Categories: CareDevelopmentDrugLearnManagementMedtechTechnology
Senhwa Biosciences Inc., a clinical stage drug development company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer.
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.12.2013 | Series B | $17M | - |
Mentions in press and media 3
| Date | Title | Description |
| 12.07.2024 | Senhwa Biosciences Clinical Data Abstract of Pidnarulex Accepted for Presentation at 2024 ESMO Congress | TAIPEI and SAN DIEGO, July 12, 2024 /PRNewswire/ -- Senhwa Biosciences' new drug Pidnarulex (CX-5461) has demonstrated efficacy in treating various solid tumors with BRCA2 or PALB2 gene defects. The abstract of this clinical trial has been ... |
| 12.12.2013 | Senhwa Biosciences Raises $17M in Financing Round | Senhwa Biosciences Inc., a cancer drug company based in Taiwan and San Diego, has raised $17 million in a Series B financing round.
Investors include H&Q Asia Pacific, Morningside and China Investment & Development Co. Ltd., the com... |
| 12.12.2013 | Senhwa Biosciences Raises USD$17M in Series B Financing | Senhwa Biosciences, Inc., a Taiwan and San Diego, CA-based developer of anticancer agents, raised an additional USD$17m Series B financing.
Backers included H&Q Asia Pacific, Morningside and China Investment & Development Co., Ltd.
... |
Reviews 0
